<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457639</url>
  </required_header>
  <id_info>
    <org_study_id>3085</org_study_id>
    <secondary_id>FD003085</secondary_id>
    <nct_id>NCT00457639</nct_id>
  </id_info>
  <brief_title>Cholic Acid for Hepatic Steatosis in Lipodystrophy</brief_title>
  <official_title>Phase II Study of Cholic Acid for Hepatic Steatosis in Lipodystrophy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FDA Office of Orphan Products Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of cholic acid therapy in treating lipodystrophy patients
      with hepatic steatosis. This is a randomized, double-blind, placebo-controlled cross-over
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lipodystrophies are rare disorders characterized by selective loss of adipose tissue and
      predisposition to develop insulin resistance and its associated metabolic complications such
      as dyslipidemia, diabetes mellitus and hepatic steatosis. Nonalcoholic hepatic steatosis or
      steatohepatitis caused by excessive accumulation of triglycerides in hepatocytes, in fact, is
      a common feature of these disorders. Often a cause for significant morbidity and even
      mortality in lipodystrophic patients, hepatic steatosis poses a significant therapeutic
      challenge. Recent insight into the role of primary bile acids, cholic acid and
      chenodeoxycholic acid, which are endogenous ligands for the farnesoid X receptor (FXR), in
      regulating hepatic triglyceride homeostasis offers new treatment options for hepatic
      steatosis. Cholic acid was shown to inhibit hepatic triglyceride accumulation by more than
      50% in a mouse model of hepatic steatosis and hypertriglyceridemia. Cholic acid has been
      previously used to treat inborn errors of bile acid synthesis in children without any side
      effects. In other studies in adults, cholic acid has been reported to be well tolerated.
      Therefore, we propose to investigate a potentially safe therapeutic option for its efficacy
      in reducing hepatic steatosis in patients with lipodystrophies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic Triglyceride (%)</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by proton magnetic resonance spectroscopy (MRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Triglycerides</measure>
    <time_frame>Months 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hepatic Steatosis</condition>
  <arm_group>
    <arm_group_label>Cholic Acid active capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cholic Acid weight based dose for 6 months double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Cholic Acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Cholic Acid for 6 months double-blind</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholic Acid</intervention_name>
    <description>Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.</description>
    <arm_group_label>Cholic Acid active capsules</arm_group_label>
    <arm_group_label>Placebo for Cholic Acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with lipodystrophies as diagnosed by clinical criteria.

          -  Hepatic steatosis (&gt;5.6% hepatic triglyceride content) as demonstrated by 1H magnetic
             resonance spectroscopy.

          -  Age 6-70 years.

          -  Alcohol intake of less than 40 g per week.

        Exclusion Criteria:

          -  Laboratory or other histologic findings highly suggestive of liver disease due to
             causes other than non-alcoholic steatohepatitis, such as chronic viral hepatitis,
             autoimmune hepatitis, primary biliary cirrhosis, biliary obstruction or genetic liver
             diseases such as Wilson's disease, hemochromatosis or alpha-1-antitrypsin deficiency.

          -  Treatment with drugs associated with steatohepatitis, e.g., corticosteroids, high dose
             estrogens, methotrexate, amiodarone, , sulfasalazine, or oxacillin in the 6 months
             prior to the study.

          -  Decompensated liver disease as evidenced by clinical features of hepatic failure
             (variceal bleeding, ascites, hepatic encephalopathy etc.) and laboratory
             investigations (prolonged prothrombin time, hypoalbuminemia, presence of esophageal
             varices etc.)

          -  Evidence of hepatocellular carcinoma: alpha-fetoprotein levels greater than 200 ng/ml
             and/or liver mass on imaging study suggestive of liver cancer.

          -  Use of drugs which can potentially decrease hepatic steatosis during previous 3
             months; ursodeoxycholic acid, high-dose vitamin E, betaine, acetylcysteine and
             choline. Thiazolidinediones are allowed if dose has been stable for 3 months prior to
             screening.

          -  Significant systemic or major illnesses other than liver disease, such as congestive
             heart failure, cerebrovascular disease, respiratory failure, renal failure (serum
             creatinine &gt;2 mg/dL), acute pancreatitis, organ transplantation, serious psychiatric
             disease, and malignancy, that could interfere with the trial and adequate follow up.

          -  Acute medical illnesses precluding participation in the studies.

          -  Known HIV-infected patient.

          -  Current substance abuse.

          -  Pregnant or lactating women.

          -  Hematocrit of less than 30%. - History of weight loss during past 3 months.

          -  Patients on bile acid binding resins, cholestyramine, colestipol, colesevelam.

          -  Hypersensitivity or intolerance to CA or any components of its formulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhimanyu Garg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ahmad Z, Subramanyam L, Szczepaniak L, Simha V, Adams-Huet B, Garg A. Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial. Eur J Endocrinol. 2013 Apr 15;168(5):771-8. doi: 10.1530/EJE-12-0969. Print 2013 May.</citation>
    <PMID>23447519</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 4, 2007</study_first_submitted>
  <study_first_submitted_qc>April 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2007</study_first_posted>
  <results_first_submitted>October 11, 2018</results_first_submitted>
  <results_first_submitted_qc>December 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 15, 2019</results_first_posted>
  <last_update_submitted>January 16, 2019</last_update_submitted>
  <last_update_submitted_qc>January 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Abhimanyu Garg</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>lipodystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment December 2006 through April 2010. A total of 37 subjects were screened for this trial.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cholic Acid Then Placebo</title>
          <description>Cholic Acid for 6 months and then Placebo for six months in a double-blind, randomized fashion</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Cholic Acid</title>
          <description>Placebo for 6 months and then Cholic Acid for 6 months in a double-blind, randomized fashion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention 1 (6 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9">6 months on Cholic Acid and crossover to Placebo for 6 months</participants>
                <participants group_id="P2" count="9">6 months on Placebo and crossover to cholic acid for 6 months</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6">Number of Patients completing Cholic Acid Phase</participants>
                <participants group_id="P2" count="7">Number of patients completing Placebo Phase</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unrelated illness</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Intervention 2 (6 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unrelated illness ineligible for MRS</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline data is for all the patients enrolled</population>
      <group_list>
        <group group_id="B1">
          <title>Characteristics of All Patients Enrolled</title>
          <description>Participants who were randomized to receive either Cholic acid or Placebo</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatic TG (%)</title>
          <units>Fat/Fat+Water (%)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.89" lower_limit="6.1" upper_limit="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Triglyceride</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="389" lower_limit="155" upper_limit="3455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hepatic Triglyceride (%)</title>
        <description>Measured by proton magnetic resonance spectroscopy (MRS)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cholic Acid</title>
            <description>Cholic Acid 6 months .</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Triglyceride (%)</title>
          <description>Measured by proton magnetic resonance spectroscopy (MRS)</description>
          <units>Fat/Fat+Water (%)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" lower_limit="10.5" upper_limit="26.5"/>
                    <measurement group_id="O2" value="14.8" lower_limit="9.4" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>13.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.7</ci_lower_limit>
            <ci_upper_limit>61.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Triglycerides</title>
        <time_frame>Months 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cholic Acid</title>
            <description>Cholic Acid 6 months .</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Triglycerides</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390" lower_limit="233" upper_limit="595"/>
                    <measurement group_id="O2" value="340" lower_limit="233" upper_limit="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.7</ci_lower_limit>
            <ci_upper_limit>50.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Diarrhea: Increased frequency of passing stool</desc>
      <group_list>
        <group group_id="E1">
          <title>Cholic Acid</title>
          <description>Cholic Acid for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Failure</sub_title>
                <description>Fluid accumulation due to hear failure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>One patient developed gastroenteritis requiring intravenous fluids</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Two patients developed diarrhea and excessive flatus while taking Cholic Acid. Their symptoms resolved after reducing the dosage.
Three other patients reported mild diarrhea which subsided within one to two weeks.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flu Like Symptoms</sub_title>
                <description>Flu like symptoms with vomiting and diarrhea.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Zahid Ahmad, M.D.</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214-648-2377</phone>
      <email>zahid.ahmad@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

